Abstract:Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3/MJD) is a progressive autosomal dominant neurodegenerative disease caused by abnormal CAG repeats in the exon 10 of ATXN3. The accumulation of the mutant ataxin-3 proteins carrying expanded polyglutamine (polyQ) leads to selective degeneration of neurons. Since the pathogenesis of SCA3 has not been fully elucidated, and no effective therapies have been identified, it is crucial to investigate the pathogenesis and seek new therapeutic strategies of SCA3. Induced pluripotent stem cells (iPSCs) can be used as the ideal cell model for the molecular pathogenesis of polyQ diseases. Abnormal CAG expansions mediated by CRISPR/Cas9 genome engineering technologies have shown promising potential for the treatment of polyQ diseases, including SCA3. In this study, SCA3-iPSCs can be corrected by the replacement of the abnormal CAG expansions (74 CAG) with normal repeats (17 CAG) using CRISPR/Cas9-mediated homologous recombination (HR) strategy. Besides, corrected SCA3-iPSCs retained pluripotent and normal karyotype, which can be differentiated into a neural stem cell (NSCs) and neuronal cells, and maintained electrophysiological characteristics. The expression of differentiation markers and electrophysiological characteristics were similar among the neuronal differentiation from normal control iPSCs (Ctrl-iPSCs), SCA3-iPSCs, and isogenic control SCA3-iPSCs. Furthermore, this study proved that the phenotypic abnormalities in SCA3 neurons, including aggregated IC2-polyQ protein, decreased mitochondrial membrane potential (MMP) and glutathione expressions, increased reactive oxygen species (ROS), intracellular Ca2+ concentrations, and lipid peroxidase malondialdehyde (MDA) levels, all were rescued in the corrected SCA3-NCs. For the first time, this study demonstrated the feasibility of CRISPR/Cas9-mediated HR strategy to precisely repair SCA3-iPSCs, and reverse the corresponding abnormal disease phenotypes. In addition, the importance of genetic control using CRISPR/Cas9-mediated iPSCs for disease modeling. Our work may contribute to providing a potential ideal model for molecular mechanism research and autologous stem cell therapy of SCA3 or other polyQ diseases, and offer a good gene therapy strategy for future treatment.

miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3.

Research on Screening and Identification of Proteins Interacting with Ataxin-3.

PolyQ-expanded Ataxin-3 Interacts with Full-Length Ataxin-3 in a Polyq Length-Dependent Manner

Small Molecules Inducing Autophagic Degradation of Expanded Polyglutamine Protein through Interaction with Both Mutant ATXN3 and LC3

Polyglutamine-expanded Ataxin3 Alter Specific Gene Expressions Through Changing DNA Methylation Status in SCA3/MJD

MicroRNA-409-3p Targeting at ATXN3 Reduces the Apoptosis of Dopamine Neurons Based on the Profile of Mirnas in the Cerebrospinal Fluid of Early Parkinson's Disease

Polyglutamine-expanded ataxin-3 is degraded by autophagy

Sumo-1 Modification On K166 Of Polyq-Expanded Ataxin-3 Strengthens Its Stability And Increases Its Cytotoxicity

Determining The Fate Of Neurons In Sca3: Atx3, A Rising Decision Maker In Response To Dna Stresses And Beyond

CRISPR/Cas9&nbsp;Mediated Gene Modification Ameliorates Abnormal Phenotypes in SCA3/MJD&nbsp;Disease Patient Derived Induced Pluripotent Stem Cells

CRISPR/Cas9 Mediated Gene Correction Ameliorates Abnormal Phenotypes in Spinocerebellar Ataxia Type 3 Patient-Derived Induced Pluripotent Stem Cells

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch

Aggregation of Polyglutamine-Expanded Ataxin-3 Sequesters Its Specific Interacting Partners into Inclusions: Implication in a Loss-of-function Pathology

MicroRNAs and polyglutamine diseases]

Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation.

Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3

[Screening for Proteins Interacting with Ataxin-3, the Gene Product of SCA3/MJD].

Investigating the therapeutic effects of novel compounds targeting inflammatory IL-1β and IL-6 signaling pathways in spinocerebellar ataxia type 3

Alteration of methylation status in the ATXN3 gene promoter region is linked to the SCA3/MJD.

Cerebellar Lncrna Expression Profile Analysis of SCA3/MJD Mice